Drugs in Dev. Infections and Infectious Diseases
Phase I
Ireland 
Lead Product(s) : EG-009A
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Evergreen Therapeutics
Deal Size : Undisclosed
Deal Type : Agreement
Details : The purpose of the study is to evaluate the efficacy of Evergreen’s EG-009A drug candidate for the treatment of moderate to severe COVID-19 cases.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
June 18, 2021
Lead Product(s) : EG-009A
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Evergreen Therapeutics
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : SARS-CoV-2 Vaccine, Live Attenuated
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Codagenix
Deal Size : Inapplicable
Deal Type : Inapplicable
Open Orphan Receoves MHRA Approval for Nasal COVID-19 Vaccine Trial
Details : The study will assess the safety and immunogenicity of a single-dose nasal vaccine candidate COVI-VAC in 48 healthy young adult volunteers.
Product Name : Covi-vac
Product Type : Vaccine
Upfront Cash : Inapplicable
December 14, 2020
Lead Product(s) : SARS-CoV-2 Vaccine, Live Attenuated
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Codagenix
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
